| Drug Name |
Teduglutide recombinant |
| Drug ID |
BADD_D02138 |
| Description |
Teduglutide is a glucagon-like peptide-2 (GLP-2) analogue. It is made up of 33 amino acids and is manufactured using a strain of Escherichia coli modified by recombinant DNA technology. Teduglutide differs from GLP-2 by one amino acid (alanine is substituted by glycine). The significance of this substitution is that teduglutide is longer acting than endogenous GLP-2 as it is more resistant to proteolysis from dipeptidyl peptidase-4. FDA approved on December 21, 2012. |
| Indications and Usage |
Treatment of short bowel syndrome (SBS), malabsorption associated with the removal of the intestine, in adults patients who are dependent on parenteral support. |
| Marketing Status |
Not Available |
| ATC Code |
A16AX08 |
| DrugBank ID |
DB08900
|
| KEGG ID |
D06053
|
| MeSH ID |
C494910
|
| PubChem ID |
70683012
|
| TTD Drug ID |
D00RCI
|
| NDC Product Code |
41524-0009; 68875-0103; 68225-087; 68875-0101; 17337-0264; 63557-1031; 68594-001; 68875-0102 |
| Synonyms |
teduglutide | Gly(2)-GLP-2 | (Gly2)GLP-2 |
